France plans a 13% cut to manufacturer reimbursement prices for paracetamol starting in 2027, sparking industry pushback over reshoring goals
Executive summary: The French government said it will lower the price manufacturers receive for paracetamol by 13% beginning in 2027. The price cut conflicts with the state's aim to reshore paracetamol production and strengthen domestic drug supply.
Who is involved: French Ministry of Health/Economy, domestic pharmaceutical manufacturers producing paracetamol.
Likely next: Industry groups are expected to lobby against the measure, and the proposal will proceed through legislative channels for implementation.
The French government announced that, as of 2027, it will reduce the price paid to paracetamol manufacturers by 13 percent. Pharmaceutical companies argue that the move undermines recent efforts to reshore production and secure national supply. The policy pits short‑term cost containment against longer‑term sovereignty objectives in the healthcare sector.
Timeline
- — L’Etat veut baisser le prix du paracétamol, les laboratoires dénoncent un projet incompatible avec la relocalisation de sa production (Le Monde — Économie)
Analysis — what this means
Sectors affected
- Paracetamol manufacturing
- Pharmaceutical supply chain
Regulatory implications
- French government to enforce a 13% reduction in manufacturer reimbursement prices for paracetamol effective 2027